CBTadvisors is a strategic consultancy supporting the biotech industry,
the life science venture capital industry and the technology transfer field.
We provide services in the development, writing and revision of key strategic
documents such as business plans and white papers, based on a subtle
understanding of the private financing markets. CBTadvisors has delivered
market and competitive analyses to clients in both large and small biotech
as well as the pharmaceutical industry in areas ranging from biopharmaceuticals
to tools to small molecule therapeutics, vaccines and medical devices.
We have also done projects for clients in venture capital and
private equity, providing due diligence and valuation analysis of
single companies and entire portfolios.
CEO Steven Dickman possesses a rare combination of venture capital, biomedical
science and science journalism expertise. He carried out biochemistry research at
Princeton University and the German Cancer Research Center and has published
numerous articles in journals such as Nature, Science and the Economist.
Most recently, he was a Principal at Techno Venture Management where, over
four years, he reviewed hundreds of investment opportunities and managed or
co-managed investments in tools, therapeutics and diagnostics.
Visit Steve's blog Boston Biotech Watch.
For more information, please contact CBTadvisors.